1. Clinical & Scientific Overview
Silodosin (Uroselective Alpha-1A Blocker for BPH) (TIP-MED-000240, Reference Code [12.8]) is classified under
Urological & Renal Stone Medicines (Ch 12) as a Highly Uroselective Alpha-1A Adrenergic Receptor Antagonist.
Within the Indian regulatory and compendial framework, it is governed under Schedule H Prescription Drug (To be sold by retail on the prescription of a Registered Medical Practitioner only — Drugs Rules 1945).
Representative Indian Market Examples (Edition 2.7 Ch 12 [12.8], p. 158): Silofast, Rapilif, Geripod, Sildoo (FDC with Dutasteride: Silofast-D, Rapilif-D) — Strengths & Dosage Forms: Capsule / Tablet: 4 mg, 8 mg; FDC with Dutasteride 0.5 mg.
Capsule / Tablet: 4 mg, 8 mg; FDC with Dutasteride 0.5 mg.
3. Mechanism of Action & Pharmacodynamics
Ultra-high selectivity for prostatic, bladder-neck, and urethral alpha-1A receptors over vascular alpha-1B receptors (162:1 selectivity) -> relaxes smooth muscle outflow resistance with minimal orthostatic blood pressure drop.
4. Therapeutic Indications & Evidence-Supported Uses
- Symptomatic benign prostatic hyperplasia (BPH) with lower urinary tract symptoms (LUTS)
🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.
5. Educational Dosage Context, Formulations & Administration
Educational Dosing & Regimen Summary: Adult: 8 mg PO once daily with a meal. • Paediatric: Not indicated in children.
Administration & Meal Timing: See Administration & Counselling below. | Standard clinical schedule per indication.
6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment
Absorption, distribution, metabolism, and excretion follow class pharmacokinetic profile; verify patient renal/hepatic function.
Renal: Moderate CKD (eGFR 30-50 mL/min): Reduce dose to 4 mg once daily with food. Severe CKD (eGFR <30 mL/min): Contraindicated. • Hepatic: Mild-to-moderate: No adjustment. Severe hepatic impairment (Child-Pugh C): Contraindicated.
Renal: Moderate CKD (eGFR 30-50 mL/min): Reduce dose to 4 mg once daily with food. Severe CKD (eGFR <30 mL/min): Contraindicated. • Hepatic: Mild-to-moderate: No adjustment. Severe hepatic impairment (Child-Pugh C): Contraindicated.
Renal: Moderate CKD (eGFR 30-50 mL/min): Reduce dose to 4 mg once daily with food. Severe CKD (eGFR <30 mL/min): Contraindicated. • Hepatic: Mild-to-moderate: No adjustment. Severe hepatic impairment (Child-Pugh C): Contraindicated.
7. Contraindications, Precautions & High-Risk Warnings
- Contraindications: Severe renal impairment (CrCl <30 mL/min); severe hepatic impairment; concomitant strong CYP3A4 or P-gp inhibitors (Ketoconazole, Itraconazole, Ritonavir, Clarithromycin). • Precautions: Intraoperative Floppy Iris Syndrome (IFIS) during cataract surgery (inform ophthalmologist even if stopped months earlier); causes reversible retrograde ejaculation/anejaculation in ~28% of men.
Key Clinical Precautions: Renal: Moderate CKD (eGFR 30-50 mL/min): Reduce dose to 4 mg once daily with food. Severe CKD (eGFR <30 mL/min): Contraindicated. • Hepatic: Mild-to-moderate: No adjustment. Severe hepatic impairment (Child-Pugh C): Contraindicated.
8. Adverse Effects Profile
- Retrograde ejaculation (orgasm with reduced/absent seminal emission), dizziness, nasal congestion, diarrhoea.
- Intraoperative Floppy Iris Syndrome (IFIS), orthostatic syncope.
- Monitor for severe hypersensitivity, organ toxicity, or dose-limiting adverse events.
9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions
- Strong CYP3A4 inhibitors (Ketoconazole, Itraconazole, Clarithromycin) -> 3-fold surge in silodosin levels (CONTRAINDICATED); PDE5 inhibitors (Sildenafil, Tadalafil) -> postural hypotension
10. Clinical Monitoring, Patient Counselling & Storage
Clinical & Laboratory Monitoring: Monitor clinical response, baseline renal/hepatic parameters, and relevant serum biomarkers.
Pharmacist Patient Counselling Points:
- Patient Counselling Checklist: Always take WITH a meal (taking on an empty stomach increases peak levels and dizziness); inform your eye surgeon before cataract surgery; reduced/absent semen volume during ejaculation is harmless and reversible.
- Meal & Clock Timing Instruction: See Administration & Counselling below. (Standard clinical schedule per indication.)
- Missed Dose Protocol: Take as soon as remembered unless close to next scheduled dose; never double the dose.
- Geriatric Dispensing Pearl: Schedule: Schedule H | NLEM 2022: Non-NLEM | Compendia: IP 2026 / NFI 7th Ed 2026 / CDSCO Schedule H / BNF 90th Ed
Storage, Stability & Dispensing Safeguards: Store below 25°C–30°C in original moisture- and light-resistant packaging out of reach of children. Available forms: Capsule / Tablet: 4 mg, 8 mg; FDC with Dutasteride 0.5 mg.
11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)
12. Authoritative References, Regulatory Sources & Editorial Disclaimer
Primary Compendial & Guideline Reference: Indian Pharmacist Desk Reference — Professional Edition 2.7 (2026–27) • Ch 12 [12.8] (p. 158)
Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)
Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: HANDBOOK_SOURCE_CONTENT
Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.
13. Related Reference Monographs, Educational Guides & Visual Concept
💊 Related Pharmacological / Category Profiles
- [12.1] Tamsulosin Hydrochloride (and Silodosin / Alfuzosin comparison) — Uroselective Alpha-1A and Alpha-1D Adrenoceptor Antagonist (Relax
- [12.2] Finasteride (and Dutasteride comparison) — 5-Alpha-Reductase Inhibitor (5-ARI; Blocks Intracellular Conversi
- [12.3] Solifenacin Succinate — Urinary Bladder-Selective Muscarinic M3-Receptor Antagonist (Anti
- [12.4] Mirabegron — Selective Beta-3 Adrenoceptor Agonist (Relaxes Detrusor Smooth Mu